United States-based Pfizer has received priority review from the US Food and Drug Administration (FDA) for its tafamidis meglumine form (20mg capsule) intended for the treatment of transthyretin amyloid cardiomyopathy, it is reported today.
The company filed two new drug applications with the regulator including the two forms of tafamidis, meglumine salt and free acid. It stated that tafamidis free acid form (61mg capsule) will be under standard review, while the prescription drug user fee act action date for a decision on the meglumine salt form of the drug is scheduled to be taken by the US FDA in July this year.
The product is a small molecule that has been developed to selectively bind at particular sites on the transthyretin tetramer to halt destabilisation of the transthyretin transport protein and formation of amyloid that causes transthyretin amyloid cardiomyopathy. According to Pfizer, tafamidis is the only product to complete a phase three clinical trial for efficacy, safety, and tolerability in patients with the condition.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial